- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Dishman Carbogen Amcis' Q1FY27 performance saw net revenue dip 4.3% YoY to ₹677.64 Cr, largely due to deferred CDMO projects. The company reported a net loss of ₹57.88 Cr, compared to a ₹23.41 Cr profit last year. EBITDA plunged 57.3% to ₹60.08 Cr, with margins shrinking to 8.9%.
CDMO revenue dropped 12.6% YoY to ₹534.38 Cr, as customers rescheduled about CHF 10 million worth of projects to the second half of FY27. However, the Marketable Molecules segment shined, growing 48% YoY to ₹143.26 Cr, boosted by Cholesterol sales.
Strategically, Dishman is focusing on boosting capacity utilization, diversifying client base, and expanding its ADC & Bioconjugation services. Oncology remains a key area, with 12 molecules in late-stage development. While CDMO margins were hit by fixed costs and a ₹11.73 Cr forex loss, Marketable Molecules margins are stable with full-year FY26 trends, and management expects deferred projects to boost H2FY27 results.